A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate for neratinib in patients with non-small cell lung cancer
At screening, after 1 month of treatment, and then every 2 months throughout the study
No
Puma
Study Director
Biotechnology
United States: Food and Drug Administration
3144A1-200
NCT00266877
December 2005
January 2009
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Rochester, Minnesota 55905 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |